

# Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation

**Jeong Uk Lim**

The Catholic University of Korea

**Silvia Park**

The Catholic University of Korea

**Jae-Ho Yoon**

The Catholic University of Korea

**Sung-Eun Lee**

The Catholic University of Korea

**Byung-Sik Cho**

The Catholic University of Korea

**Yoo-Jin Kim**

The Catholic University of Korea

**Seok Lee**

The Catholic University of Korea

**Hee-Je Kim**

The Catholic University of Korea

**Chin Kook Rhee** (✉ [chinkook77@gmail.com](mailto:chinkook77@gmail.com))

The Catholic University of Korea

---

## Research Article

**Keywords:** tiotropium, bronchiolitis obliterans syndrome, hematopoietic stem cell transplantation, lung, chronic graft-versus-host disease

**Posted Date:** April 14th, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1476600/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

# Abstract

**Background:** Bronchiolitis obliterans syndrome (BOS) is the lung manifestation of chronic graft-versus-host disease, and a noninfectious pulmonary sequela of hematopoietic stem cell transplantation (HSCT). Despite the combination regimen including budesonide/formoterol that was previously shown as effective, a significant proportion of patients are unresponsive. We assessed whether inhaled tiotropium add-on to the combination regimen improve pulmonary function and the chronic obstructive pulmonary disease assessment test (CAT) scores in patients with BOS.

**Methods:** Post-HSCT patients with significant respiratory symptoms or poor pulmonary function referred to the pulmonology department of the HSCT Center of Seoul St. Mary's Hospital, were reviewed retrospectively. Patients defined as BOS and treated with budesonide/formoterol/tiotropium combination therapy after budesonide/formoterol therapy from January 2011 to June 2019 were enrolled.

**Results:** Total of 86 patients were evaluated. After tiotropium add-on, the absolute FEV1 increased significantly from  $1.47 \pm 0.49$  to  $1.53 \pm 0.57$  L ( $p = 0.023$ ) and the % predicted FEV1 from  $45.0 \pm 12.8$  to  $46.8 \pm 14.5\%$  ( $p = 0.031$ ). The % predicted DLCO increased significantly after tiotropium add-on (from  $61.6 \pm 16.7$  to  $64.3 \pm 16.3\%$ ,  $p = 0.028$ ). Among 56 patients with complete CAT scores, no significant change was present in total CAT scores. In all, 30 of the 72 patients (41.7%) evidenced FEV1 increases  $> 100$  mL, and 20 of 56 patients (35.7%) had CAT score decreases of  $\geq 2$  points. When the FEV1 and CAT scores were combined, the overall response rate to tiotropium add-on was 56.2% (41/73). The response group evidenced a significantly greater FVC increase (both absolute ( $p < 0.001$ ) and % predicted ( $p < 0.001$ )), and a significant decrease in the RV/TLC ratio compared to the no-response group ( $p = 0.006$ ).

**Conclusions:** Inhaled tiotropium add-on to combination budesonide/formoterol significantly improved lung function, but not respiratory symptoms, in patients with post-HSCT BOS.

## Introduction

Bronchiolitis obliterans syndrome (BOS) is the lung manifestation of chronic graft-versus-host disease (cGVHD)(1), a noninfectious pulmonary sequela of hematopoietic stem cell transplantation (HSCT) that features progressive fibrosis of the small terminal airways and *de novo* fixed airflow obstruction(2, 3). The National Institutes of Health consensus on cGVHD recommends diagnostic criteria for BOS(4). The prevalence of BOS in allogeneic HCT recipients is about 2–3%(5–7). BOS can be fatal; the overall survival rate is  $< 50\%$  at 2 years(8). Current treatments for post-HSCT BOS include systemic or inhaled corticosteroids, long-acting beta-2 agonists, leukotriene receptor antagonists, and azithromycin(1, 9–11). However, systemic steroids were ineffective(12) and may also compromise the efficacy of immunomodulatory treatment. Inhalers act locally, and thus lack systemic side effects; more effort should be devoted to the development of inhaled bronchodilators. We previously found that a treatment regimen including budesonide/formoterol was effective(10, 13). A combination of budesonide/formoterol, montelukast, and n-acetylcysteine significantly improved lung function and

respiratory symptoms(10). However, a significant proportion of patients became unresponsive over time. A new treatment regimen is essential for such patients. We empirically added inhaled tiotropium to a combination including budesonide/formoterol when treating patients who did not respond to the tiotropium-free combination. We sought improvements in pulmonary function and the chronic obstructive pulmonary disease assessment test (CAT) scores.

## Methods

### Patients

Post-HSCT patients with significant respiratory symptoms or poor pulmonary function were referred to the pulmonology department of the HSCT Center of Seoul St. Mary's Hospital, Seoul, Korea. A single experienced pulmonologist (Rhee CK) treated and followed-up patients with BOS, using the same protocol. After retrospective chart review, patients treated with budesonide/formoterol/tiotropium combination therapy after budesonide/formoterol therapy from January 2011 to June 2019 were enrolled. The inclusion criteria were chronic GVHD in other organs and a positive diagnostic pulmonary function test (PFT) using the modified National Institute of Health criteria,(3, 14) and tiotropium use for at least 2 months (after addition to budesonide/formoterol. The exclusion criteria were any other pulmonary or infectious disease (asthma, chronic obstructive pulmonary disease, lung cancer, interstitial lung disease, pneumonia, or tubercular lungs), no history of previous budesonide/formoterol, and a history of other inhaler use. Approval was obtained from the institutional review board of Seoul St. Mary's Hospital, which waived the requirement for informed consent (KC22RIS10155).

### Definition of BOS

The diagnostic criteria for BOS were fibrogenic deposits in the small airways or bronchioles of patients who underwent lung biopsies in patients who did not undergo biopsies or have chronic GVHD in other organs or air-trapping evident in high-resolution computed tomography (HRCT), and who had a positive PFT (the modified NIH criteria) (3, 12, 14). In terms of PFT parameters, the modified NIH criteria are a forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio < 0.7, an FEV1 < 75% of that predicted with  $\geq 10\%$  decline over < 2 years, absence of respiratory tract infection, air-trapping evident in expiratory CT or the PFT, and a residual volume (RV) > 120% that predicted or an RV/total lung capacity ratio outside the 90% confidence interval(13, 15). All HRCT scans were read by a single radiology specialist (Jung JI (10, 16-18)) who reviewed inspiratory before expiratory images. Air-trapping was considered present in expiratory images when certain lung regions failed to exhibit increases in attenuation and/or decreases in volume compared to those of the inspiratory images(7). Patients who satisfied the diagnostic criteria but lacked active infectious disease were diagnosed with BOS.

### Tiotropium add-on

Prior to addition of tiotropium, all patients had been treated with budesonide/formoterol, montelukast, and n-acetylcysteine; all received 160  $\mu\text{g}$  budesonide and 4.5  $\mu\text{g}$  formoterol fumarate via a dry powder

inhaler (Symbicort Turbuhaler; AstraZeneca, Mölndal, Sweden) twice daily, 10 mg oral montelukast daily, and 200 mg oral n-acetylcysteine three times daily. After the clinician (Rhee CK) decided to add tiotropium, HandiHaler or Respimat inhalers were prescribed (one and two puffs daily, respectively).

## Responders

After 3 months of add-on therapy, patients were grouped by their PFT results and CAT scores. A therapeutic response was defined by reference to the minimum clinically important difference (MCID); this distinguishes a small meaningless change from a small but meaningful change(19). The MCIDs for the FEV1 and CAT score are 100 mL(20) and 2 points respectively(21). The responsive group evidenced FEV1 increases > 100 mL or CAT score decreases  $\geq 2$ .

## Statistics

All statistical analyses were performed using the Statistical Package for the Social Sciences (ver. 20.0; SPSS Inc., Chicago, IL, USA). Continuous data are presented as means with ranges; the Student t-test was used to compare normally distributed continuous variables and the Mann-Whitney U-test to compare non-normally distributed continuous variables. The chi-square test was employed to compare categorical variables. The paired t-test was used to compare normally distributed parameters before and after tiotropium add-on. When parameters were non-normally distributed, the Wilcoxon rank test was performed. A p-value < 0.05 was considered significant.

# Results

## Baseline clinical characteristics

Table 1 lists the baseline clinical characteristics. Of the 86 patients, 45 (52.3%) were male. The mean age was  $45.9 \pm 12.7$  years. Of underlying hematological diseases, acute myeloid leukemia (AML) was the most common (43.0%) followed by acute lymphoblastic leukemia (ALL) (27.9%). The mean duration between hematopoietic stem cell transplantation and BOS diagnosis was  $20.0 \pm 16.5$  months. In terms of acute GVHD, 50 (62.5%) patients were so diagnosed. Chronic GVHD of the skin, oral cavity and eyes were most frequently noted.

Table 1

Clinical characteristics of patients with bronchiolitis obliterans syndrome (n=86)

	Number (%)
Recipient sex, male	45 (52.3%)
Recipient age	45.9±12.7
Hematologic diseases	
AML	37 (43.0%)
ALL	24 (27.9%)
CML	3 (3.5%)
NHL	3 (3.5%)
MDS	16 (18.6%)
AA	3 (3.5%)
Donor type (n=80)	
Unrelated	34 (42.5%)
Sibling	29 (36.3%)
FMT	17 (21.3%)
HLA (n=74)	
full-match	49 (66.2%)
mismatch	25 (33.8%)
Stem cell source (n=81)	
PB	68 (84%)
BM	13 (16%)
Time from HSCT to BOS diagnosis, months	20.0±16.5
Acute GVHD (n=82)	50 (62.5%)
Chronic GVHD (except lung) (n=85)	
Skin	31 (36.5%)
Oral	47 (55.3%)
Eyes	23 (27.1%)
Liver	20 (23.5%)

GI tract	5 (5.9%)
Joint	3 (3.5%)
Sicca	17 (20.0%)
Systemic steroid use	80 (93.0%)
Tacrolimus	35 (40.7%)
Cyclosporin	22 (25.6%)
Mycophenolate mofetil	37 (43.0%)

**Abbreviations:** AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; NHL, non-hodgkin lymphoma; MDS, myelodysplastic syndrome; AA, aplastic anemia; FMT, familial mismatched transplantation; HLA, human leukocyte antigens; PB, peripheral blood; BM, bone marrow; HSCT, hematopoietic stem cell transplantation; BOS, bronchiolitis obliterans syndrome; GVHD, graft versus host disease

### **Pulmonary function changes after tiotropium add-on**

Table 2 and Fig. 1 show the pulmonary function parameters when tiotropium was added and 3 months later. After add-on, no significant change was observed in the percentage predicted or absolute FEV<sub>1</sub> value. The absolute FEV<sub>1</sub> increased significantly from  $1.47 \pm 0.49$  to  $1.53 \pm 0.57$  L ( $p = 0.023$ ) and the % predicted FEV<sub>1</sub> from  $45.0 \pm 12.8$  to  $46.8 \pm 14.5\%$  ( $p = 0.031$ ). The FEV<sub>1</sub>/FVC ratio increased from  $56.4 \pm 18.7$  to  $57.2 \pm 17.8\%$  ( $p = 0.041$ ). No significant change in the RV/TLC ratio was observed. The % predicted diffusing capacity for carbon monoxide (DLCO) increased significantly after tiotropium add-on (from  $61.6 \pm 16.7$  to  $64.3 \pm 16.3\%$ ,  $p = 0.028$ ).

Table 2  
Changes of pulmonary function test and CAT score (before and after tiotropium add on)

Clinical variable	At time of tiotropium add on	After tiotropium add on	Changes in lung function or symptom score	P-value
FVC (absolute)	2.77 ± 0.95	2.82 ± 1.02	0.05 ± 0.40	0.268
FVC (% predicted)	69.0 ± 16.9	70.4 ± 18.3	1.4 ± 10.0	0.074
FEV1 (absolute)	1.47 ± 0.49	1.53 ± 0.57	0.06 ± 0.23	0.023
FEV1 (% predicted)	45.0 ± 12.8	46.8 ± 14.5	1.8 ± 7.0	0.031
FEV1/FVC (%)	56.4 ± 18.7	57.2 ± 17.8	1.2 ± 4.3	0.041
RV/TLC (%)	40.9 ± 9.3	40.5 ± 8.4	-0.4 ± 6.2	0.601
DLCO (% predicted)	61.6 ± 16.7	64.3 ± 16.3	2.7 ± 10.7	0.028

**Abbreviations:** CAT, COPD assessment test; DLCO, diffusing capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; RV/TLC, residual volume to total lung capacity ratio

### CAT score changes after tiotropium add-on

Fifty-six patients completed the CAT questionnaires at both the time of tiotropium add-on and 3 months later (Table 3). The CAT score did not change significantly over time ( $p = 0.833$ ). The median score at the time of tiotropium add-on was 16 (10.25–22) but 15 (10.25–21.75) 3 months later. Only the answers to question 4 (breathlessness increasing) and 8 (energy) differed significantly over time. The CAT 4 score fell from 4 (3–4) to 3 (2.25–4) ( $p = 0.038$ ) and the CAT 8 score increased from 2 (1–3) to 3 (2–3) ( $p = 0.006$ ).

Table 3  
Changes of COPD assessment test (CAT) score after tiotropium add-on (n = 56)

Clinical variable	Tiotropium add on	After tiotropium add-on	P-value
Q1. Cough	1 (0–3)	1 (0.25-3)	0.833
Q2. Phlegm	2 (0.25-3)	2 (1–3)	0.151
Q3. Chest tightness	2 (0.25-3)	1 (0–3)	0.186
Q4. Breathlessness going up	4 (3–4)	3 (2.25-4)	0.038
Q5. Activity limitation at home	1 (0–3)	1 (0–3)	0.156
Q6. Confidence leaving home	2 (0.25-3)	1 (0–3)	0.335
Q7. Sleep	1 (0-2.75)	2 (1–3)	0.242
Q8. Energy	2 (1–3)	3 (2–3)	0.006
<b>Total sum of the eight items</b>	16 (10.25-22.0)	15 (10.25–21.75)	0.725

Data represent the median (IQR). P-values shown in bold are significant at the 0.05 level

#### Therapeutic responses and associations with pulmonary function change

The therapeutic response was an improvement in the FEV1 or CAT score. In all, 30 of the 72 patients (41.7%) evidenced FEV1 increases > 100 mL (Fig. 2A); 20 of 56 patients (35.7%) had CAT score decreases  $\geq 2$  points (Fig. 2B). When the FEV1 and CAT scores were combined, the overall response rate to tiotropium add-on was 56.2% (41/73) (Fig. 2C). We found no significant difference in baseline characteristics between the no-response and response groups, with the exceptions of underlying hematological disease and chronic GVHD status (Table 4). The PFT and CAT scores at the time of tiotropium add-on did not affect the therapeutic response (Table 5). However, changes in the FVC and FEV1, and the FEV1/FVC and RV/TLC ratios, between the time of tiotropium add-on and 3 months later differed significantly. The response group evidenced a significantly greater FVC increase (both absolute [ $-0.21 \pm 0.34$  vs.  $0.25 \pm 0.31$  mL,  $p < 0.001$ ] and % predicted [ $-5.0 \pm 9.8\%$  vs.  $6.2 \pm 6.9\%$ ,  $p < 0.001$ ]) and a significant decrease in the RV/TLC ratio compared to the no-response group ( $-2.3 \pm 5.7$  vs.  $2.6 \pm 6.0$ ,  $p = 0.006$ ).



Table 4

Comparison of clinical characteristics between therapeutic response group and no-response group

Clinical parameters	No-response group	Response group	p-value
Number	32	41	
Recipient sex, male	13 (40.6%)	24 (58.5%)	0.129
Recipient age	43.6±13.1	47.2±12.5	0.221
Hematologic diseases			
AML	15 (46.9%)	16 (39.0%)	0.501
ALL	6 (18.8%)	12 (29.3%)	0.301
CML	3 (9.4%)	0 (0.0%)	0.045
NHL	3 (9.4%)	0 (0.0%)	0.045
MDS	5 (15.6%)	11 (26.8%)	0.251
AA	0 (0.0%)	2 (4.9%)	0.205
Donor type (n=68)	(n=28)	(n=40)	0.680
Unrelated	9 (32.1%)	17 (42.5%)	
Sibling	12 (42.9%)	14 (35.0%)	
FMT	7 (25.0%)	9 (22.5%)	
HLA (n=63)	(n=26)	(n=37)	0.794
full-match	17 (65.4%)	23 (62.2%)	
mismatch	9 (34.6%)	14 (37.8%)	
Stem cell source (n=69)	(n=28)	(n=41)	0.574
PB	24 (85.7%)	33 (80.5%)	
BM	4 (14.3%)	8 (19.5%)	
Time from HSCT to BOS diagnosis, months	16.4±11.1	19.7±15.3	0.298
	(n=29)	(n=40)	
Acute GVHD (n=69)	17 (58.6%)	30 (75.0%)	0.150
Chronic GVHD (except lung) (n=72)			
Skin	14 (45.2%)	14 (34.1%)	0.342
Oral	14 (45.2%)	25 (61.0%)	0.182
Eyes	9 (29.0%)	10 (24.4%)	0.658

Liver	9 (29.0%)	8 (19.5%)	0.346
GI tract	2 (6.5%)	3 (7.3%)	0.886
Joint	3 (9.7%)	0 (0.0%)	0.042
Sicca	6 (19.4%)	9 (22.0%)	0.788
Systemic steroid use	31 (96.9%)	36 (87.8%)	0.162
Tacrolimus	13 (40.6%)	16 (39.0%)	0.890
Cyclosporin	11 (34.4%)	11 (26.8%)	0.486
Mycophenolate mofetil	16 (50.0%)	15 (36.6%)	0.250

**Abbreviations:** AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; NHL, non-hodgkin lymphoma; MDS, myelodysplastic syndrome; AA, aplastic anemia; FMT, familial mismatched transplantation; HLA, human leukocyte antigens; PB, peripheral blood; BM, bone marrow; HSCT, hematopoietic stem cell transplantation; BOS, bronchiolitis obliterans syndrome; GVHD, graft versus host disease

Table 5  
Comparison of baseline pulmonary function and CAT score between response and no-response group.

	No-response group	Response group	p-value
Tiotropium add on			
FVC (absolute)	2.62 ± 0.93	2.88 ± 0.97	0.119
FVC (% predicted)	67.6 ± 16.8	70.0 ± 17.1	0.785
FEV1 (absolute)	1.36 ± 0.42	1.55 ± 0.53	0.122
FEV1 (% predicted)	42.8 ± 11.3	46.7 ± 13.7	0.295
FEV1/FVC (%)	55.6 ± 20.2	56.4 ± 17.3	0.513
RV/TLC (%)	41.2 ± 11.6	41.0 ± 7.8	0.834
DLCO (% predicted)	60.6 ± 17.4	62.8 ± 15.6	0.438
CAT score	14.5 ± 7.8	18.0 ± 7.4	0.077
Δ FVC (absolute)	-0.21 ± 0.34*	0.25 ± 0.31*	< 0.001
Δ FVC (% predicted)	-5.0 ± 9.8*	6.2 ± 6.9*	< 0.001
Δ FEV1 (absolute)	-0.12 ± 0.14*	0.20 ± 0.20*	< 0.001
Δ FEV1 (% predicted)	-3.3 ± 5.7*	5.7 ± 5.3*	< 0.001
Δ FEV1/FVC (%)	0.2 ± 4.8	1.9 ± 3.8*	0.048
Δ RV/TLC (%)	2.6 ± 6.0	-2.3 ± 5.7*	0.006
Δ DLCO (% predicted)	-0.65 ± 11.3	4.83 ± 9.91*	0.069
Δ CAT score	4.4 ± 4.5*	-3.1 ± 6.0*	< 0.001

\* Indicates significant with-in group change according to Wilcoxon-rank test or Paired T test.

**Abbreviations:** CAT, COPD assessment test; DLCO, diffusing capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; RV/TLC, residual volume to total lung capacity ratio

## Discussion

We evaluated the utility of tiotropium add-on in BOS patients previously treated with budesonide/formoterol; we assessed the responses of both respiratory symptoms and pulmonary function. Tiotropium add-on significantly improved the FEV1. We earlier showed that the rapid lung function loss in patients with post-HSCT BOS was associated with poorer pulmonary function and overall

survival than those of a group evidencing gradual declines.(22) It is essential to prevent lung function decline, thus to stabilize disease. The current treatment regimens include systemic or inhaled corticosteroids, long-acting beta-2 agonists, leukotriene receptor antagonists, and azithromycin(1, 9–11). Compared to our previous study of patients receiving budesonide/formoterol, the proportion who exhibited an overall response was smaller (56 vs. 82%) although we used the same MCID criteria (10). This was also evident when the CAT scores and FEV1 values were compared. The study groups differed; our present patients had previously received combination budesonide/formoterol and none evidenced no or reduced therapeutic response. Thus, addition of inhaled tiotropium was valuable.

The principal BOS pathophysiology post-HSCT is irreversible small airway narrowing attributable to fibrotic changes (23); inhaled bronchodilators would thus be expected to be less efficacious than in patients with other airway diseases(24–26) in whom airway reversibility is (at least somewhat) preserved. However, to reduce BOS progression and preserve the remaining lung function, we thought it important to assess the efficacies of inhaled bronchodilators in BOS patients. We previously showed that the combination of budesonide/formoterol, montelukast, and n-acetylcysteine significantly improved the lung function and respiratory symptoms of BOS patients(10). However, many patients did not respond; a new treatment was essential. We found that add-on tiotropium aided the subgroup non-responsive to budesonide/formoterol.

Why did tiotropium improve the mean FEV1 and the DLCO? Importantly, the improvements were not attributable to tiotropium alone, rather to the synergistic effects of tiotropium and budesonide/formoterol. Efficacy of the combination bronchodilator therapies were shown in studies on COPD patients (27, 28). As tiotropium efficacy in post-HSCT BOS patients has received little attention, it was appropriate to review the COPD works. Combinations of a long-acting beta-agonist and a long-acting muscarinic antagonist improve bronchodilation more so than either drug alone (29). In an animal model, tiotropium inhibited airway remodeling including extracellular matrix deposition (ECM) (30). Tiotropium triggered airway smooth muscle cell relaxation and prevented ECM deposition(30). However, the effects of tiotropium on the small airways of post-HSCT BOS patients require further evaluation.

Our work had certain limitations. The therapeutic responses were assessed using PFT and CAT scores obtained 3 months after tiotropium add-on; we lack data on long-term effects and further studies are needed. We did not evaluate the effect of inhaled tiotropium alone; the observed therapeutic response may be attributable to only tiotropium or the combination treatment. However, the CAT and PFT scores were measured before and after tiotropium initiation. Finally, this was not a randomized controlled study, rather a retrospective cohort work. However, all patients were treated by the same expert pulmonologist who adhered to a defined protocol.

## Conclusions

Inhaled tiotropium add-on to combination budesonide/formoterol significantly improved lung function, but not respiratory symptoms, in patients with post-HSCT BOS.

## Abbreviations

BOS: bronchiolitis obliterans syndrome; HSCT: hematopoietic stem cell transplantation; CAT: chronic obstructive pulmonary disease assessment test; cGVHD: chronic graft-versus-host disease; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; HRCT: high-resolution computed tomography; RV: residual volume; MCID: minimum clinically important difference; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; DLCO: diffusing capacity for carbon monoxide

## Declarations

### Acknowledgements

Not applicable.

### Authors' contributions

RCK was responsible for study concept and design. PS, YJ, LS, CB, KY, LS, KH, and RCK contributed to patient recruitment and follow-up. All authors contributed to data acquisition.

LJU and RCK performed data analysis. LJU and RCK contributed to the drafting of this manuscript. All authors read and approved the final manuscript.

### Funding

Not applicable.

### Availability of data and materials

All data generated or analysed during this study are included in this published article.

### Declarations

Approval was obtained from the institutional review board of Seoul St. Mary's Hospital, which waived the requirement for informed consent (KC22RIS10155).

### Consent for publication

Not applicable.

### Competing interests

CK Rhee received consulting/lecture fees from MSD, AstraZeneca, GSK, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, Sanofi, and Bayer.


## References

1. Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. *Blood*. 2017;129(4):448–55.
2. Chien JW. Preventing and managing bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. *Expert review of respiratory medicine*. 2011;5(1):127–35.
3. Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. *Jama*. 2009;302(3):306–14.
4. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. *Biol Blood Marrow Transplant*. 2005;11(12):945–56.
5. Santo Tomas LH, Loberiza FR, Jr., Klein JP, Layde PM, Lipchik RJ, Rizzo JD, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. *Chest*. 2005;128(1):153–61.
6. Marras TK, Chan CK, Lipton JH, Messner HA, Szalai JP, Laupacis A. Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation. *Bone Marrow Transplant*. 2004;33(5):509–17.
7. Rhee CK, Ha JH, Yoon JH, Cho BS, Min WS, Yoon HK, et al. Risk Factor and Clinical Outcome of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. *Yonsei medical journal*. 2016;57(2):365–72.
8. Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. *Biol Blood Marrow Transplant*. 2010;16(1 Suppl):S106-14.
9. Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2016;22(4):710–6.
10. Kim SW, Rhee CK, Kim YJ, Lee S, Kim HJ, Lee JW. Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. *Respiratory research*. 2016;17(1):63.
11. Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, et al. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. *Jama*. 2017;318(6):557–66.
12. Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. *The New England journal of medicine*. 2014;370(19):1820–8.
13. Kim KH, Lee J, Kim HJ, Lee S, Kim YJ, Lee JH, et al. Efficacy and safety of high-dose budesonide/formoterol in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplant. *J Thorac Dis*. 2020;12(8):4183–95.
14. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2011;17(7):1072–8.

15. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. *Biol Blood Marrow Transplant*. 2015;21(3):389–401 e1.
16. Jung JI, Jung WS, Hahn ST, Min CK, Kim CC, Park SH. Bronchiolitis obliterans after allogeneic bone marrow transplantation: HRCT findings. *Korean J Radiol*. 2004;5(2):107–13.
17. Oh JK, Jung JI, Han DH, Ahn MI, Park SH, Cho BS, et al. Multidetector row computed tomography quantification of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation: a pilot study. *J Thorac Imaging*. 2013;28(2):114–20.
18. Choi MH, Jung JI, Chung WD, Kim YJ, Lee SE, Han DH, et al. Acute pulmonary complications in patients with hematologic malignancies. *Radiographics*. 2014;34(6):1755–68.
19. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. *Controlled clinical trials*. 1989;10(4):407–15.
20. Donohue JF. Minimal clinically important differences in COPD lung function. *Copd*. 2005;2(1):111–24.
21. Kon SS, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. *Lancet Respir Med*. 2014;2(3):195–203.
22. Kwok WC, Liang BM, Lui MMS, Tam TCC, Sim JPY, Tse EWC, et al. Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome. *Respirology*. 2019;24(5):459–66.
23. Chambers DC. Bronchiolitis obliterans syndrome 'endotypes' in haematopoietic stem cell transplantation. *Respirology*. 2019;24(5):408–9.
24. O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. *The New England journal of medicine*. 2018;378(20):1865–76.
25. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. *The European respiratory journal*. 2003;21(1):74–81.
26. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. *The European respiratory journal*. 2003;22(6):912–9.
27. Welte T, Miravittles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*. 2009;180(8):741–50.
28. Lee SD, Xie CM, Yunus F, Itoh Y, Ling X, Yu WC, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia. *Respirology*. 2016;21(1):119–27.

29. Rhee CK, Yoshisue H, Lad R. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives. *Adv Ther.* 2019;36(3):495–519.
30. Pera T, Zuidhof A, Valadas J, Smit M, Schoemaker RG, Gosens R, et al. Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD. *The European respiratory journal.* 2011;38(4):789–96.


## Figures



**Figure 1**

Comparison of pulmonary function parameters when tiotropium was added and 3 months later; (A) FVC (%), FEV<sub>1</sub> (%), and FEV<sub>1</sub>/FVC (%), (B) FVC (L) and FEV<sub>1</sub> (L), (C) RV/TLC (%) and DLCO (%),

**Abbreviations:** DLCO, diffusing capacity of the lungs for carbon monoxide; FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity; RV/TLC, residual volume to total lung capacity ratio





## Figure 2

Comparison of response and no-response groups by (A) FEV<sub>1</sub> increases > 100 mL, (B) by CAT score decreases  $\geq$  2 points, (C) when FEV<sub>1</sub> and CAT scores were combined

**Abbreviations:** CAT, COPD assessment test; FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity; RV/TLC, residual volume to total lung capacity ratio